TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy of Different Strategies to Treat Anemia in Mexican Children: A Randomized Clinical Trial
Brief Summary: Anemia continues to be a major public health problem in many regions of the world and it is still not clear which strategy is more effective in children population in terms of adherence and efficacy. The objective was to evaluate the efficacy and acceptance of several strategies that have been recently recommended to treat anemia on anemic children (6 to 43 mo):Iron supplement, iron+folic acid supplement, a multiple micronutrients supplement a micronutrient fortified complementary food in the form of porridge powder or zinc+iron+ascorbic acid fortified water.


Options:
A: Arm Label: Anemic children; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Iron, Dietary Supplement: Multiple micronutrients supplement, Dietary Supplement: micronutrient fortified porridge powder, Dietary Supplement: Iron and ascorbic acid fortified water, Dietary Supplement: Iron plus folic acid supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron; Assigned to Arm(s): Anemic children | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple micronutrients supplement; Assigned to Arm(s): Anemic children | Intervention Type: DIETARY_SUPPLEMENT; Name: micronutrient fortified porridge powder; Assigned to Arm(s): Anemic children | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron and ascorbic acid fortified water; Assigned to Arm(s): Anemic children | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron plus folic acid supplement; Assigned to Arm(s): Anemic children
B: Arm Label: Fortified Yoghurt; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Fortified Yoghurt | Arm Label: Yoghurt; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Yoghurt | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Fortified Yoghurt; Assigned to Arm(s): Fortified Yoghurt | Intervention Type: DIETARY_SUPPLEMENT; Name: Yoghurt; Assigned to Arm(s): Yoghurt
C: Arm Label: Tomato Meal; Type: OTHER; Interventions: Other: Post-prandial Feeding Study | Arm Label: Carrot Meal; Type: OTHER; Interventions: Other: Post-prandial Feeding Study | Intervention Type: OTHER; Name: Post-prandial Feeding Study; Assigned to Arm(s): Carrot Meal, Tomato Meal
D: Intervention Type: DRUG; Name: Micronutrient (Zinc and Iron) fortification; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Pre and Probiotic fortification; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy of Different Strategies to Treat Anemia in Mexican Children: A Randomized Clinical Trial
Brief Summary: Anemia continues to be a major public health problem in many regions of the world and it is still not clear which strategy is more effective in children population in terms of adherence and efficacy. The objective was to evaluate the efficacy and acceptance of several strategies that have been recently recommended to treat anemia on anemic children (6 to 43 mo):Iron supplement, iron+folic acid supplement, a multiple micronutrients supplement a micronutrient fortified complementary food in the form of porridge powder or zinc+iron+ascorbic acid fortified water.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: fortified spread (RUTF); Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: maize and soy flour; Assigned to Arm(s): N/A
B: Arm Label: Anemic children; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Iron, Dietary Supplement: Multiple micronutrients supplement, Dietary Supplement: micronutrient fortified porridge powder, Dietary Supplement: Iron and ascorbic acid fortified water, Dietary Supplement: Iron plus folic acid supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron; Assigned to Arm(s): Anemic children | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple micronutrients supplement; Assigned to Arm(s): Anemic children | Intervention Type: DIETARY_SUPPLEMENT; Name: micronutrient fortified porridge powder; Assigned to Arm(s): Anemic children | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron and ascorbic acid fortified water; Assigned to Arm(s): Anemic children | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron plus folic acid supplement; Assigned to Arm(s): Anemic children
C: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nutritional supplement; Type: EXPERIMENTAL; Interventions: Other: Nutritional supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Nutritional supplement; Assigned to Arm(s): Nutritional supplement | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Dietary supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Corn Soya Blend+ | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Corn Soya Blend+; Assigned to Arm(s): Dietary supplement

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Controlled Trial of Retransfusion of Intra-operatively Collected Filtered Whole Blood in Total Hip Surgery
Brief Summary: The study is a prospective, controlled, randomised and assessor blind study that investigate if the need for bank blood transfusion could be reduced in patients, undergoing primary or revision total hip replacement surgery, who receive their own blood back with the medical device Sangvia.

A comparison in need for bank blood will be made between patients that either receive their own blood back or not.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Sangvia® System | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Sangvia® System; Assigned to Arm(s): 1
B: Arm Label: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Type: ACTIVE_COMPARATOR; Interventions: Other: Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Arm Label: Allowed drop in hemoglobin to 5.6-6.5 mmol/L; Type: EXPERIMENTAL; Interventions: Other: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 5.6-6.5 mmol/L
C: Arm Label: Liberal Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive transfusion strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive transfusion strategy
D: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Double Blind, Placebo-Controlled Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection on 30 Day Recurrence Rates.
Brief Summary: Patients will be enrolled in a multi-center study (Wilford Hall Medical Center and Brooke Army Medical Center) to prospectively evaluate outcome after treatment for an uncomplicated skin abscess.


Options:
A: Arm Label: Bactrim DS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trim/ Sulfa DS | Arm Label: matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Trim/ Sulfa DS; Assigned to Arm(s): Bactrim DS | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): matched placebo
B: Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo group | Arm Label: antibiotic group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trimethoprim-sulfamethoxazole | Intervention Type: DRUG; Name: Trimethoprim-sulfamethoxazole; Assigned to Arm(s): antibiotic group | Intervention Type: DRUG; Name: Placebo group; Assigned to Arm(s): placebo group
C: Arm Label: Linezolid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linezolid | Arm Label: CEM-102 Regimen A; Type: EXPERIMENTAL; Interventions: Drug: CEM-102 | Arm Label: CEM-102 Regimen B; Type: EXPERIMENTAL; Interventions: Drug: CEM-102 | Intervention Type: DRUG; Name: CEM-102; Assigned to Arm(s): CEM-102 Regimen A | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid | Intervention Type: DRUG; Name: CEM-102; Assigned to Arm(s): CEM-102 Regimen B
D: Arm Label: Moxifloxacin; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039) | Arm Label: PIP/TAZ-AMC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid | Intervention Type: DRUG; Name: Moxifloxacin (Avelox, BAY12-8039); Assigned to Arm(s): Moxifloxacin | Intervention Type: DRUG; Name: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid; Assigned to Arm(s): PIP/TAZ-AMC

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Pilot Study to Evaluate the Effect of Preoperative Antithrombin Supplementation on Postoperative Levels of Antithrombin in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
Brief Summary: The purpose of this trial is to study the effects of preoperative antithrombin supplementation in patients undergoing cardiac surgery with cardiopulmonary bypass in order to maintain antithrombin levels in a range greater than 58% of functional activity and, eventually, to decrease negative clinical outcomes during the ICU stay.


Options:
A: Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Warfarin vs ASA; Assigned to Arm(s): N/A
C: Arm Label: Antithrombin III treatment group; Type: EXPERIMENTAL; Interventions: Drug: Antithrombin III | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antithrombin III; Assigned to Arm(s): Antithrombin III treatment group
D: Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: Desirudin (Iprivask™); Type: EXPERIMENTAL; Interventions: Drug: Desirudin (Iprivask™) | Intervention Type: DRUG; Name: Desirudin (Iprivask™); Assigned to Arm(s): Desirudin (Iprivask™) | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Fresh Embryo Transfers be Replaced by Cryopreserved-thawed Embryo Transfers in Assisted Reproductive Cycles?
Brief Summary: Cryopreservation of all embryos and transferring them subsequently in assisted reproductive technology (ART) cycles to improve outcome.


Options:
A: Arm Label: fresh embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: fresh embryo transfer | Arm Label: frozen-thawed embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: frozen-thawed embryo transfer | Intervention Type: OTHER; Name: fresh embryo transfer; Assigned to Arm(s): fresh embryo transfer group | Intervention Type: OTHER; Name: frozen-thawed embryo transfer; Assigned to Arm(s): frozen-thawed embryo transfer group
B: Arm Label: frozen-embryo transfer; Type: ACTIVE_COMPARATOR; Interventions: Procedure: freezing embryos by vitrification, Drug: buserelin, Drug: recombinant FSH, Drug: human chorionic gonadotropin (pregnyl) | Arm Label: fresh embryo transfer; Type: ACTIVE_COMPARATOR; Interventions: Procedure: fresh embryo transfers, Drug: buserelin, Drug: recombinant FSH, Drug: human chorionic gonadotropin (pregnyl) | Intervention Type: PROCEDURE; Name: freezing embryos by vitrification; Assigned to Arm(s): frozen-embryo transfer | Intervention Type: PROCEDURE; Name: fresh embryo transfers; Assigned to Arm(s): fresh embryo transfer | Intervention Type: DRUG; Name: buserelin; Assigned to Arm(s): fresh embryo transfer, frozen-embryo transfer | Intervention Type: DRUG; Name: recombinant FSH; Assigned to Arm(s): fresh embryo transfer, frozen-embryo transfer | Intervention Type: DRUG; Name: human chorionic gonadotropin (pregnyl); Assigned to Arm(s): fresh embryo transfer, frozen-embryo transfer
C: Arm Label: Blastocyst transfer in PTEC cycle; Type: EXPERIMENTAL; Interventions: Procedure: Embryo cryopreservation | Arm Label: Fresh blastocyst transfer.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh blastocyst transfer | Intervention Type: PROCEDURE; Name: Embryo cryopreservation; Assigned to Arm(s): Blastocyst transfer in PTEC cycle | Intervention Type: PROCEDURE; Name: Fresh blastocyst transfer; Assigned to Arm(s): Fresh blastocyst transfer.
D: Arm Label: Freeze-all protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Freeze-all protocol | Arm Label: Fresh transfer protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh transfer protocol | Intervention Type: PROCEDURE; Name: Freeze-all protocol; Assigned to Arm(s): Freeze-all protocol | Intervention Type: PROCEDURE; Name: Fresh transfer protocol; Assigned to Arm(s): Fresh transfer protocol

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Fresh Embryo Transfers be Replaced by Cryopreserved-thawed Embryo Transfers in Assisted Reproductive Cycles?
Brief Summary: Cryopreservation of all embryos and transferring them subsequently in assisted reproductive technology (ART) cycles to improve outcome.


Options:
A: Arm Label: Blastocyst transfer in PTEC cycle; Type: EXPERIMENTAL; Interventions: Procedure: Embryo cryopreservation | Arm Label: Fresh blastocyst transfer.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh blastocyst transfer | Intervention Type: PROCEDURE; Name: Embryo cryopreservation; Assigned to Arm(s): Blastocyst transfer in PTEC cycle | Intervention Type: PROCEDURE; Name: Fresh blastocyst transfer; Assigned to Arm(s): Fresh blastocyst transfer.
B: Arm Label: fresh embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: fresh embryo transfer | Arm Label: frozen-thawed embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: frozen-thawed embryo transfer | Intervention Type: OTHER; Name: fresh embryo transfer; Assigned to Arm(s): fresh embryo transfer group | Intervention Type: OTHER; Name: frozen-thawed embryo transfer; Assigned to Arm(s): frozen-thawed embryo transfer group
C: Arm Label: frozen-embryo transfer; Type: ACTIVE_COMPARATOR; Interventions: Procedure: freezing embryos by vitrification, Drug: buserelin, Drug: recombinant FSH, Drug: human chorionic gonadotropin (pregnyl) | Arm Label: fresh embryo transfer; Type: ACTIVE_COMPARATOR; Interventions: Procedure: fresh embryo transfers, Drug: buserelin, Drug: recombinant FSH, Drug: human chorionic gonadotropin (pregnyl) | Intervention Type: PROCEDURE; Name: freezing embryos by vitrification; Assigned to Arm(s): frozen-embryo transfer | Intervention Type: PROCEDURE; Name: fresh embryo transfers; Assigned to Arm(s): fresh embryo transfer | Intervention Type: DRUG; Name: buserelin; Assigned to Arm(s): fresh embryo transfer, frozen-embryo transfer | Intervention Type: DRUG; Name: recombinant FSH; Assigned to Arm(s): fresh embryo transfer, frozen-embryo transfer | Intervention Type: DRUG; Name: human chorionic gonadotropin (pregnyl); Assigned to Arm(s): fresh embryo transfer, frozen-embryo transfer
D: Arm Label: Corifollitropin alfa 150 μg; Type: EXPERIMENTAL; Interventions: Biological: Corifollitropin alfa | Arm Label: recFSH 300 IU; Type: ACTIVE_COMPARATOR; Interventions: Biological: recFSH (follitropin beta) | Intervention Type: BIOLOGICAL; Name: Corifollitropin alfa; Assigned to Arm(s): Corifollitropin alfa 150 μg | Intervention Type: BIOLOGICAL; Name: recFSH (follitropin beta); Assigned to Arm(s): recFSH 300 IU

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Palliative Care for Quality of Life and Symptom Concerns in Early Stage Lung Cancer
Brief Summary: RATIONALE: Palliative care may be more effective than standard care in improving quality of life and symptoms in patients with lung cancer.

PURPOSE: This clinical trial is studying the effects of palliative care on quality of life and symptom control in patients with stage I, stage II, or stage IIIA non-small cell lung cancer that can be removed by surgery.


Options:
A: Arm Label: Phase 1 Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: medical chart review, Other: questionnaire administration, Procedure: end-of-life treatment/management, Procedure: psychosocial assessment and care, Procedure: quality-of-life assessment | Arm Label: Phase 2 Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: educational intervention, Other: medical chart review, Other: questionnaire administration, Procedure: end-of-life treatment/management, Procedure: psychosocial assessment and care, Procedure: quality-of-life assessment | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): Phase 2 Intervention | Intervention Type: OTHER; Name: medical chart review; Assigned to Arm(s): Phase 1 Usual care, Phase 2 Intervention | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): Phase 1 Usual care, Phase 2 Intervention | Intervention Type: PROCEDURE; Name: end-of-life treatment/management; Assigned to Arm(s): Phase 1 Usual care, Phase 2 Intervention | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): Phase 1 Usual care, Phase 2 Intervention | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Phase 1 Usual care, Phase 2 Intervention
B: Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Other: early palliative care | Arm Label: early palliative care; Type: ACTIVE_COMPARATOR; Interventions: Other: early palliative care | Intervention Type: OTHER; Name: early palliative care; Assigned to Arm(s): control, early palliative care
C: Arm Label: Early palliative care consultation; Type: EXPERIMENTAL; Interventions: Other: Early palliative care consultation | Arm Label: Care as usual; Type: OTHER; Interventions: Other: Care as usual | Intervention Type: OTHER; Name: Early palliative care consultation; Assigned to Arm(s): Early palliative care consultation | Intervention Type: OTHER; Name: Care as usual; Assigned to Arm(s): Care as usual
D: Arm Label: Early entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early palliative care intervention | Arm Label: Later entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Later entry group | Intervention Type: BEHAVIORAL; Name: Later entry group; Assigned to Arm(s): Later entry group | Intervention Type: BEHAVIORAL; Name: Early palliative care intervention; Assigned to Arm(s): Early entry group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Controlled, Phase II, Double-Blind Trial of Intramyocardial Injection of Autologous Bone Marrow Mononuclear Cells Under Electromechanical Guidance for Patients With Chronic Ischemic Heart Disease and Left Ventricular Dysfunction
Brief Summary: Coronary artery disease (CAD) is a common disorder that can lead to heart failure. Not all people with CAD are eligible for today's standard treatments. One new treatment approach uses stem cells-specialized cells capable of developing into other types of cells-to stimulate growth of new blood vessels for the heart. This study will determine the safety and effectiveness of withdrawing stem cells from someone's bone marrow and injecting those cells into the person's heart as a way of treating people with CAD and heart failure.


Options:
A: Arm Label: Placebo Injections; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Active Stem Cell Injections; Type: EXPERIMENTAL; Interventions: Biological: Adult stem cells | Intervention Type: BIOLOGICAL; Name: Adult stem cells; Assigned to Arm(s): Active Stem Cell Injections | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Injections
B: Intervention Type: PROCEDURE; Name: Intramyocardial injection of autologous CD133+ marrow cells; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous human mesenchymal cells (hMSCs) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous human bone marrow cells (hBMCs) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Autologous human mesenchymal cells (hMSCs); Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Autologous human bone marrow cells (hBMCs); Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: CD133+ autologous bone marrow stem cells; Type: ACTIVE_COMPARATOR; Interventions: Drug: CD133+ autologous bone marrow stem cell | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CD133+ autologous bone marrow stem cell; Assigned to Arm(s): CD133+ autologous bone marrow stem cells | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A